Inovio Pharmaceuticals Inc. (NASDAQ:INO) went down by -3.39% from its latest closing price compared to the recent 1-year high of $33.79. The company’s stock price has collected -19.80% of loss in the last five trading sessions. Press Release reported on 02/26/21 that INOVIO INVESTIGATION INITIATED by Former Louisiana Attorney General: Kahn Swick & Foti, LLC Investigates the Officers and Directors of Inovio Pharmaceuticals Inc. – INO
Is It Worth Investing in Inovio Pharmaceuticals Inc. (NASDAQ :INO) Right Now?
Plus, the 36-month beta value for INO is at 0.97. Opinions of the stock are interesting as 3 analysts out of 9 who provided ratings for Inovio Pharmaceuticals Inc. declared the stock was a “buy,” while 0 rated the stock as “overweight,” 5 rated it as “hold,” and 1 as “sell.”
The average price from analysts is $15.13, which is $4.03 above the current price. INO currently public float of 166.76M and currently shorts hold a 25.84% ratio of that float. Today, the average trading volume of INO was 15.92M shares.
INO’s Market Performance
INO stocks went down by -19.80% for the week, with a monthly drop of -11.20% and a quarterly performance of 9.36%, while its annual performance rate touched 154.59%. The volatility ratio for the week stands at 9.53% while the volatility levels for the past 30 days are set at 13.62% for Inovio Pharmaceuticals Inc.. The simple moving average for the period of the last 20 days is -17.35% for INO stocks with a simple moving average of -21.18% for the last 200 days.
Analysts’ Opinion of INO
Many brokerage firms have already submitted their reports for INO stocks, with Oppenheimer repeating the rating for INO by listing it as a “Outperform.” The predicted price for INO in the upcoming period, according to Oppenheimer is $35 based on the research report published on February 12th of the current year 2021.
ROTH Capital gave a rating of “Neutral” to INO, setting the target price at $8 in the report published on November 10th of the previous year.
INO Trading at -1.34% from the 50-Day Moving Average
After a stumble in the market that brought INO to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -67.15% of loss for the given period.
Volatility was left at 13.62%, however, over the last 30 days, the volatility rate increased by 9.53%, as shares surge +1.37% for the moving average over the last 20 days. Over the last 50 days, in opposition, the stock is trading +6.63% upper at present.
During the last 5 trading sessions, INO fell by -19.80%, which changed the moving average for the period of 200-days by -13.95% in comparison to the 20-day moving average, which settled at $13.44. In addition, Inovio Pharmaceuticals Inc. saw 25.42% in overturn over a single year, with a tendency to cut further gains.
Reports are indicating that there were more than several insider trading activities at INO starting from BENITO SIMON X, who sale 2,000 shares at the price of $14.68 back on Feb 16. After this action, BENITO SIMON X now owns 51,650 shares of Inovio Pharmaceuticals Inc., valued at $29,360 using the latest closing price.
Kim Jong Joseph, the Chief Executive Officer of Inovio Pharmaceuticals Inc., sale 62,500 shares at $14.24 during a trade that took place back on Feb 03, which means that Kim Jong Joseph is holding 1,078,313 shares at $890,000 based on the most recent closing price.
Stock Fundamentals for INO
Current profitability levels for the company are sitting at:
- -2855.31 for the present operating margin
The net margin for Inovio Pharmaceuticals Inc. stands at -2902.75. The total capital return value is set at -122.34, while invested capital returns managed to touch -127.11. Equity return is now at value -103.00, with -52.70 for asset returns.
Based on Inovio Pharmaceuticals Inc. (INO), the company’s capital structure generated 2,896.79 points at debt to equity in total, while total debt to capital is 96.66. Total debt to assets is 65.46, with long-term debt to equity ratio resting at 2,836.39. Finally, the long-term debt to capital ratio is 94.65.
When we switch over and look at the enterprise to sales, we see a ratio of 82.13, with the company’s debt to enterprise value settled at 0.29. The receivables turnover for the company is 1.35 and the total asset turnover is 0.03. The liquidity ratio also appears to be rather interesting for investors as it stands at 2.94.